NEOS Investment Management LLC Acquires 33,962 Shares of Abbott Laboratories $ABT

Key Points

• NEOS Investment Management increased its Abbott Laboratories holdings by 13.6% in the second quarter, adding 33,962 shares for a total position of 284,296 shares valued at approximately $25.8 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts maintain a positive outlook, with Abbott receiving a consensus “Moderate Buy” rating and an average price target of $119.50. Recent target changes included upgrades from Citigroup and Wells Fargo, while UBS lowered its target to $125.
• Abbott reported quarterly EPS of $1.31, beating estimates by $0.03, while revenue rose 13% year over year to $12.59 billion. The company also declared a quarterly dividend of $0.63, equivalent to a 2.3% annualized yield.

NEOS Investment Management LLC lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 13.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 284,296 shares of the healthcare product maker's stock after purchasing an additional 33,962 shares during the period. NEOS Investment Management LLC's holdings in Abbott Laboratories were worth $25,797,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cornerstone Financial Management LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth $25,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter worth $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Citigroup lifted their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 6th. Finally, UBS Group decreased their target price on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a research report on Tuesday, July 28th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $119.50.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $108.29 on Monday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The company has a market cap of $187.38 billion, a PE ratio of 35.05, a P/E/G ratio of 2.01 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The business has a 50-day simple moving average of $104.43 and a two-hundred day simple moving average of $100.03.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories's dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source